Is Severe Cardiac Dysfunction a Contraindication for Complex Combined Oncotherapy of Hodgkin's Lymphoma? Not Any More

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10192766" target="_blank" >RIV/00216208:11110/13:10192766 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/13:10192766 RIV/00179906:_____/13:10192766 RIV/00023001:_____/13:00058693

Výsledek na webu

<a href="http://dx.doi.org/10.1097/MAT.0b013e318289b992" target="_blank" >http://dx.doi.org/10.1097/MAT.0b013e318289b992</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MAT.0b013e318289b992" target="_blank" >10.1097/MAT.0b013e318289b992</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Is Severe Cardiac Dysfunction a Contraindication for Complex Combined Oncotherapy of Hodgkin's Lymphoma? Not Any More

Popis výsledku v původním jazyce

Hodgkin's lymphoma is a quite frequent diagnosis, particularly in younger patients, which is normally treated effectively with combined chemotherapy and radiotherapy. Cardiomyopathy induced by these treatments is not uncommon and may progress to advanced-stage heart failure. Due to the cardiotoxicity of chemotherapy for Hodgkin's disease, preexisting heart failure precludes usual therapy. We present a novel strategy of hemodynamic stabilization with an implantable left ventricular assist device (LVAD) prior to radical oncotherapy for Hodgkin's lymphoma. A 33-year-old man with a short history of progressive heart failure was hospitalized due to progressive symptoms. An echocardiogram revealed a dilated left ventricle with an ejection fraction of 18%, moderate right ventricular dysfunction, and moderate to severe tricuspid regurgitation. Supradiaphragmatic-stage Hodgkin's lymphoma was also diagnosed. Due to severe cardiac dysfunction, the patient was not a candidate for the usual chemoth

Název v anglickém jazyce

Is Severe Cardiac Dysfunction a Contraindication for Complex Combined Oncotherapy of Hodgkin's Lymphoma? Not Any More

Popis výsledku anglicky

Hodgkin's lymphoma is a quite frequent diagnosis, particularly in younger patients, which is normally treated effectively with combined chemotherapy and radiotherapy. Cardiomyopathy induced by these treatments is not uncommon and may progress to advanced-stage heart failure. Due to the cardiotoxicity of chemotherapy for Hodgkin's disease, preexisting heart failure precludes usual therapy. We present a novel strategy of hemodynamic stabilization with an implantable left ventricular assist device (LVAD) prior to radical oncotherapy for Hodgkin's lymphoma. A 33-year-old man with a short history of progressive heart failure was hospitalized due to progressive symptoms. An echocardiogram revealed a dilated left ventricle with an ejection fraction of 18%, moderate right ventricular dysfunction, and moderate to severe tricuspid regurgitation. Supradiaphragmatic-stage Hodgkin's lymphoma was also diagnosed. Due to severe cardiac dysfunction, the patient was not a candidate for the usual chemoth

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ASAIO Journal

ISSN

1058-2916

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

320-321

Kód UT WoS článku

000330472400020

EID výsledku v databázi Scopus

—